Empirical analysis shows better event-free survival in r/r DLBCL patients receiving third-line CAR-T therapy, suggesting its effectiveness over alternative treatments.
Key Points
Improved event-free survival associated with CAR-T therapy was observed among matched patients.
After 18 months, EFS was 43.5% for CAR-T patients versus 24.7% for alternative treatments.
Analysis used propensity score matching to balance key clinical covariates across treatment groups.
Findings support the use of CAR-T as a valuable option for third-line therapy in eligible patients.